Literature DB >> 8551999

Behavioral and neurochemical effects of chronic methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys.

D L Frederick1, S F Ali, W Slikker, M P Gillam, R R Allen, M G Paule.   

Abstract

Effects of chronic treatment with the putative serotonergic neurotoxicant MDMA were assessed in rhesus macaques using behavior in an operant test battery (OTB) designed to model aspects of time estimation, short-term memory, motivation, learning, and color and position discrimination. After an initial acute dose-response assessment, escalating doses of MDMA (0.10-20.0 mg/kg, im, twice daily, for 14 consecutive days at each dose) were administered, followed by three additional acute dose-response assessments. In general, tolerance to MDMA's acute effects was evident in all OTB tasks by the second week of repeated exposure to each individual MDMA dose and as doses escalated. Baseline OTB performance after chronic treatment was not significantly altered. Residual behavioral tolerance to MDMA's acute effects, however, was evident in all OTB tasks but was least pronounced in the motivation task. Monkeys were sacrificed (21 months after chronic treatment) and brains were dissected into several regions for neurochemical analyses. Serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) were analyzed via HPLC. Although MDMA-treated monkeys tended to have lower 5-HT concentrations in the frontal cortex, chronic MDMA treatment had no significant effects on 5-HT concentrations in any brain area sampled. Hippocampal 5-HIAA concentration, 5-HT uptake sites, and turnover of 5-HT of MDMA-treated monkeys were significantly lower than control values. DA concentrations in the CN of MDMA-treated monkeys were significantly greater than control values. No significant effects on DA concentrations were noted in any other brain area sampled. The absence of significant decreases in 5-HT and the general increase in DA concentrations are dissimilar to neurochemical effects reported after a short course of MDMA treatment at relatively high doses. These data suggest that chronic administration of gradually increasing doses of MDMA results in long-lasting tolerance to the drugs acute effects on the complex brain functions modeled in the OTB. It is uncertain, however, if such tolerance is related to the observed decreases in uptake sites and turnover of 5-HT in the hippocampus of these monkeys.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8551999     DOI: 10.1016/0892-0362(95)00013-h

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  9 in total

1.  Effects of repeated 3,4-methylenedioxymethamphetamine administration on neurotransmitter efflux and sensory-evoked discharge in the ventral posterior medial thalamus.

Authors:  M A Starr; M E Page; B D Waterhouse
Journal:  J Pharmacol Exp Ther       Date:  2011-10-07       Impact factor: 4.030

2.  The nature of ecstasy-group related deficits in associative learning.

Authors:  Catharine Montgomery; John E Fisk; Russell Newcombe
Journal:  Psychopharmacology (Berl)       Date:  2005-01-25       Impact factor: 4.530

3.  Rats preexposed to MDMA display attenuated responses to its aversive effects in the absence of persistent monoamine depletions.

Authors:  Daniel L Albaugh; Jennifer A Rinker; Michael H Baumann; Jacquelyn R Sink; Anthony L Riley
Journal:  Psychopharmacology (Berl)       Date:  2011-03-05       Impact factor: 4.530

4.  Cognitive Effects of MDMA in Laboratory Animals: A Systematic Review Focusing on Dose.

Authors:  Madeline M Pantoni; Stephan G Anagnostaras
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

5.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

Review 6.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

7.  Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates.

Authors:  William E Fantegrossi; Rayna M Bauzo; Daniel M Manvich; Jose C Morales; John R Votaw; Mark M Goodman; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2009-05-07       Impact factor: 4.530

8.  Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges.

Authors:  M H Baumann; R D Clark; F H Franken; J J Rutter; R B Rothman
Journal:  Neuroscience       Date:  2008-01-12       Impact factor: 3.590

9.  NMDA receptor subunit and CaMKII changes in rat hippocampus induced by acute MDMA treatment: a mechanism for learning impairment.

Authors:  S Moyano; D Frechilla; J Del Río
Journal:  Psychopharmacology (Berl)       Date:  2004-02-25       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.